Shkreli jury ends first day of deliberations without verdict
NEW YORK — The first day of jury deliberations at the federal securities fraud trial of Martin Shkreli ended Monday without a verdict for the former biotech CEO best known for hiking up the price of a life-saving drug and for trolling his critics on social media.
The deliberations, which resume Tuesday, follow about a month of testimony in federal court in Brooklyn, most it from investors in two failed hedge funds run by the defendant. The witnesses told jurors the 34-year-old Shkreli concealed the fact that he lost millions of dollars and made them the victim of a scheme to pay them back with worthless stock in a startup drug company.
The trial “has exposed Martin Shkreli for who he really is — a con man who stole millions,” a federal prosecutor, Jacquelyn Kasulis, said in closing arguments last week.
The defence countered by arguing the investors weren’t victims because they recouped their money when the drug company went public. Some even made large profits when the stock price took off.


